Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1996 Oct;201(1):167-72.
doi: 10.1148/radiology.201.1.8816539.

Common bile duct obstruction due to malignancy: treatment with plastic versus metal stents

Affiliations
Clinical Trial

Common bile duct obstruction due to malignancy: treatment with plastic versus metal stents

J Lammer et al. Radiology. 1996 Oct.

Abstract

Purpose: To compare the clinical efficacy and treatment costs of plastic versus metal biliary stents.

Materials and methods: In a randomized trial, 101 patients with malignant common bile duct obstruction underwent transhepatic stent implantation and were followed up until death. Patients were stratified into risk and nonrisk groups. Forty-nine patients received 12-F plastic stents, and 52 received expandable metal stents. Plastic endoprostheses were placed in a two-step procedure; metal stent, in a single procedure. Kaplan-Meier analyses were used to compare patient survival and stent patency rates.

Results: The 30-day mortality rate was significantly lower for metal stents (five of 52 [10%]) than plastic stents (12 of 49 [24%]; P = .05). The obstruction rate was 19% (10 of 52; median patency, 272 days) for metal stents and 27% for plastic stents (13 of 49; median patency, 96 days; P < .01). Median time until death or obstruction was longer for metal stents (122 vs 81 days; P < .01). Placement of metal stents was associated with shorter hospital stay (10 vs 21 days; P < .01) and lower cost ($7,542 vs $12,129; P < .01).

Conclusion: Use of self-expanding metal stents appears to show substantial benefits for patients and to be cost-effective.

PubMed Disclaimer

MeSH terms

LinkOut - more resources